# FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

> **NCT04758949** · PHASE2 · WITHDRAWN · sponsor: **Flame Biosciences**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** FL-101
- **DRUG:** Nivolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04758949
- **Lead sponsor:** Flame Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-25
- **Primary completion:** 2021-12-22
- **Final completion:** 2021-12-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04758949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04758949, "FL-101 in Surgically Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04758949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*